home / stock / allr / allr news

ALLR News and Press, Allarity Therapeutics Inc. From 06/04/25

Stock Information
Company Name: Allarity Therapeutics Inc.
Stock Symbol: ALLR
Market: NASDAQ
Website: allarity.com
Menu
ALLR ALLR Quote ALLR Short ALLR News ALLR Articles ALLR Message Board
Get ALLR Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLR - Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action

TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a...
ALLR - Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—toda...

ALLR - Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—toda...

ALLR - Allarity Therapeutics GAAP EPS of -$0.25

2025-05-09 16:39:23 ET More on Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha For further details see: Allarity Therapeutics GAAP EPS of -$0.25
ALLR - Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash and restricted cash balance of approximately $27 million at end...

ALLR - Allarity Therapeutics Presents Novel Drug Response Predictor-DRP®-for Daratumumab in Multiple Myeloma at AACR 2025

TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as...

ALLR - Allarity Therapeutics GAAP EPS of -$15.65

2025-03-31 17:50:17 ET More on Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha For further details see: Allarity Therapeutics GAAP EPS of -$15.65
ALLR - Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with e...

ALLR - Expected US Company Earnings on Friday, March 28th, 2025

Entera Bio Ltd. (ENTX) is expected to report $-0.08 for Q4 2024 Audacy, Inc. (AUDAQ) is expected to report for quarter end 2024-12-31 The Dixie Group Inc. (DXYN) is expected to report for quarter end 2024-12-31 POET Technologies Inc. (POET) is expected to report $-0.09 for Q4 2024 ...

ALLR - Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Boston (March 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced ...
Previous 10 Next 10